OBJECTIVE: The aim of this study was to assess the predictors of adverse clinical events (CE) and the creation and evaluation of the prognostic value of a novel personalized scoring system in patients with HF.
METHODS: The study included 113 HF patients (median age 64 years (IQR 58-69); 57.52% male). The new novel prognostic score named GLVC (G, global longitudinal peak strain (GLPS); L, left ventricular diastolic diameter (LVDD); V, oxygen pulse (VO2/HR); and C, high sensitivity C-reactive protein (hs-CRP)) was created. The Kaplan-Meier method and log-rank test were used to compare the CE.
RESULTS: Results from final analyses showed that low GLPS (< 13.9%, OR = 2.66, 95% CI = 1.01-4.30, p = 0.002), high LVDD (> 56 mm, OR = 2.37, 95% CI = 1.01-5.55, p = 0.045), low oxygen pulse (< 10, OR = 2.8, 95% CI = 1.17-6.70, p = 0.019), and high hs-CRP (> 2.38 µg/ml, OR = 2.93, 95% CI = 1.31-6.54, p = 0.007) were independent prognostic factors for adverse CE in HF population. All the patients were stratified into a low-risk or high-risk group according to a novel \"GLVC\" scoring system. The Kaplan-Meier analyses demonstrated that patients in the high-risk group were more predisposed to having higher adverse clinical events compared to patients in the low-risk group.
CONCLUSIONS: A novel and comprehensive personalized \"GLVC\" scoring system is an easily available and effective tool for predicting the adverse outcomes in HF.
目的:本研究的目的是评估不良临床事件(CE)的预测因子,并创建和评估新型个性化评分系统在HF患者中的预后价值。
方法:该研究包括113例HF患者(中位年龄64岁(IQR58-69);57.52%为男性)。新的预后评分命名为GLVC(G,全局纵向峰值应变(GLPS);L,左心室舒张内径(LVDD);V,氧脉冲(VO2/HR);和C,高敏C反应蛋白(hs-CRP)产生。使用Kaplan-Meier方法和对数秩检验来比较CE。
结果:最终分析结果显示,GLPS较低(<13.9%,OR=2.66,95%CI=1.01-4.30,p=0.002),高LVDD(>56mm,OR=2.37,95%CI=1.01-5.55,p=0.045),低氧脉冲(<10,OR=2.8,95%CI=1.17-6.70,p=0.019),和高hs-CRP(>2.38µg/ml,OR=2.93,95%CI=1.31-6.54,p=0.007)是HF人群不良CE的独立预后因素。根据新的“GLVC”评分系统,将所有患者分为低风险或高风险组。Kaplan-Meier分析表明,与低风险组患者相比,高风险组患者更容易发生更高的不良临床事件。
结论:一种新颖且全面的个性化“GLVC”评分系统是预测HF不良结局的一种简单有效的工具。